Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376530 | 0.92 | ADORA1 (0.59) | ADORA1SLC6A3 | |
| SCHEMBL8003040 | 0.90 | ADORA1 (0.56) | ADORA1SLC6A3MEN1NPC1ALDH1A1 | |
| SCHEMBL12376569 | 0.88 | ADORA1 (0.48) | ADORA1SLC6A3 | |
| SCHEMBL12376558 | 0.87 | ADORA1 (0.46) | ADORA1SLC6A3 | |
| SCHEMBL8005100 | 0.86 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL12376503 | 0.84 | ADORA1 (0.41) | ADORA1SLC6A3MEN1NPC1ALDH1A1 | |
| SCHEMBL12536075 | 0.84 | ADORA1 (0.61) | ADORA1SLC6A3MEN1NPC1ALDH1A1 | |
| SCHEMBL12376497 | 0.81 | ADORA1 (0.56) | ADORA1SLC6A3MEN1NPC1ALDH1A1 | |
| SCHEMBL12376489 | 0.81 | ADORA1 (0.56) | ADORA1SLC6A3MEN1NPC1ALDH1A1 | |
| SCHEMBL8001636 | 0.80 | ADORA1 (0.51) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426602-B2 | Heteroaryl-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, SDHA | ADORA1 3151/4885SLC6A3 1742/4885MEN1 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.